(Appeal— Orphan medicinal products— Regulation (EC) No141/2000— Regulation (EC) No847/2000
Fecha: 01-Ene-2015
8It is apparent from paragraphs10 to 20 of the judgment under appeal that by decision of 14February 2001 the Commission designated imatinib mesylate (‘imatinib’) an orphan medicinal product for the treatment of chronic myeloid leukaemia (‘CML’) and entered that product in the Community Register of Orphan Medicinal Products in accordance with Articl...